A NEW TYPHOID VACCINE COMPOSED OF THE VI CAPSULAR POLYSACCHARIDE

被引:53
作者
PLOTKIN, SA [1 ]
BOUVERETLECAM, N [1 ]
机构
[1] PASTEUR MERIEUX CONNAUGHT, Marnes La Coquette, FRANCE
关键词
D O I
10.1001/archinte.155.21.2293
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Typhoid is still prevalent in many parts of the world. We reviewed all published and unpublished studies of a newly licensed vaccine composed of the Vi capsular polysaccharide of Salmonella typhi, the causative agent of the disease, which had been licensed previously outside the United States. These included observational studies and double-blind randomized studies done in the United States, Europe, and the developing world in which children and adults unexposed to typhoid or those living in endemic areas were enrolled. A single dose of 25 mu g of the purified polysaccharide nas given by intramuscular injection The vaccine was well tolerated, inducing only minor reactions in fewer than 10% of subjects. An antibody response occurred in about 90% of subjects and lasted about 3 years. Seroconversion was shown in children as young as 2 years. Protective efficacy was evaluated in two studies conducted in areas in which typhoid is endemic; the efficacy was 55% and 75%, respectively, in adults and in children older than 5 years. The Vi vaccine compares favorably with other typhoid vaccines in regard to safety, patient compliance, immunogenicity, and efficacy. Vi polysaccharide is a well-standardized antigen that is effective in a single parenteral dose, is safer than whole-cell vaccine,and may be used in children 2 years of age or older.
引用
收藏
页码:2293 / 2299
页数:7
相关论文
共 69 条
[51]   IMMUNOGENICITY OF SALMONELLA-TYPHI TY21A VACCINE FOR YOUNG-CHILDREN [J].
MURPHY, JR ;
GREZ, L ;
SCHLESINGER, L ;
FERRECCIO, C ;
BAQAR, S ;
MUNOZ, C ;
WASSERMAN, SS ;
LOSONSKY, G ;
OLSON, JG ;
LEVINE, MM .
INFECTION AND IMMUNITY, 1991, 59 (11) :4291-4293
[52]   SAFETY AND IMMUNOGENICITY OF SALMONELLA-TYPHI TY21A LIQUID FORMULATION VACCINE IN 4-YEAR-OLD TO 6-YEAR-OLD THAI CHILDREN [J].
OLANRATMANEE, T ;
LEVINE, M ;
LOSONSKY, G ;
THISYAKORN, U ;
CRYZ, SJ .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (02) :451-452
[53]   TYPHIM-VI VACCINE - TOLERANCE AND IMMUNOGENICITY 2 STUDIES ON HEALTHY PATIENTS [J].
PETERSCHMITT, A ;
FAUCONNIER, J ;
VARICHON, JP ;
STAHL, JP ;
POIROT, P ;
MICOUD, M .
MEDECINE ET MALADIES INFECTIEUSES, 1991, 21 (11) :694-699
[54]   USE OF ORAL TYPHOID VACCINE STRAIN TY21A IN A NEW-YORK-STATE TRAVEL IMMUNIZATION FACILITY [J].
RAHMAN, S ;
BARR, W ;
HILTON, E .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1993, 48 (06) :823-826
[55]  
ROBBINS JB, 1988, MONOGR ALLERGY, V24, P315
[56]   REEXAMINATION OF THE PROTECTIVE ROLE OF THE CAPSULAR POLYSACCHARIDE (VI-ANTIGEN) OF SALMONELLA-TYPHI [J].
ROBBINS, JD ;
ROBBINS, JB .
JOURNAL OF INFECTIOUS DISEASES, 1984, 150 (03) :436-449
[57]  
RYAN CA, 1989, REV INFECT DIS, V11, P1
[58]  
SCHWARTZ E, 1990, ARCH INTERN MED, V150, P349, DOI 10.1001/archinte.150.2.349
[59]   ORAL IMMUNIZATION AGAINST TYPHOID-FEVER IN INDONESIA WITH TY21A VACCINE [J].
SIMANJUNTAK, CH ;
PALEOLOGO, FP ;
PUNJABI, NH ;
DARMOWIGOTO, R ;
TOTOSUDIRJO, SH ;
HARYANTO, P ;
SUPRIJANTO, E ;
WITHAM, ND ;
HOFFMAN, SL .
LANCET, 1991, 338 (8774) :1055-1059
[60]  
SIMANJUNTAK CH, 1994, 2ND AS PAC S TYPH FE